Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel [Yahoo! Finance]
Nexalin Technology, Inc. (NXL)
Company Research
Source: Yahoo! Finance
HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. (“Carmi Masha”), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console (“SYNC”), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a variety of mental health disorders, such as insomnia, depression, and anxiety. Nexalin and Carmi Masha also plan to explore potential future applications of the technology in post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), Alzheimer's disease, and other forms of dementia as part
Show less
Read more
Impact Snapshot
Event Time:
NXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NXL alerts
High impacting Nexalin Technology, Inc. news events
Weekly update
A roundup of the hottest topics
NXL
News
- Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease ProgramGlobeNewswire
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4GlobeNewswire
- Nexalin Technology (NASDAQ:NXL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NXL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Nexalin Technology (NASDAQ:NXL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NXL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Nexalin Technology (NASDAQ:NXL) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
NXL
Sec Filings
- 11/14/25 - Form 10-Q
- 10/15/25 - Form 424B5
- 10/15/25 - Form 8-K
- NXL's page on the SEC website